References

World Health Organization (WHO). (2021). Mental Health and Psychosocial Considerations During the COVID-19 Pandemic. 

2022 State of Mental Health in America

Operation Deep Dive

Department of Veterans Affairs (VA). (2021). Suicide Data Report, 2020. 

Centers for Disease Control and Prevention (CDC). (2021). Opioid Overdose. 

The Drug Overdose Epidemic: Behind the Numbers

Johns Hopkins Medicine. (2021). Psychedelic Research. 

MAPS (Multidisciplinary Association for Psychedelic Studies). (2021). Psychedelic-Assisted Therapies.

Beckley Foundation. (2021). Drug Policy Reform.

Drug Policy Alliance. (2021). Psychedelics.

David Nutt et al. (2010). Development of a rational scale to assess the harm of drugs of potential misuse. Lancet, 376(9752), 1558-1565.

Drug Policy Alliance. (2021). Alcohol and Other Drugs.

National Institute on Alcohol Abuse and Alcoholism (NIAAA). (2021). Alcohol's Effects on the Body.

Nutt, D. J., King, L. A., & Phillips, L. D. (2010). Drug harms in the UK: a multicriteria decision analysis. The Lancet, 376(9752), 1558-1565.

John Hopkins Study on Mystical Type Experiences for Normal Users

London Imperial College Therapeutic Potential of Psilocybin Past, Present, and Future

Psilocybin Produces Substantial & Sustained Decreases in Depression & Anxiety in Patients with Life-Threatening Cancer

Psilocybin for Treatment-Resistant depression: fMRI-measured brain mechanisms

Rapid and Sustained Symptom Reduction Following Psilocybin Treatment for Anxiety and Depression in Patients with life-threatening Cancer

Psilocybin-Assisted Treatment for Alcohol Dependence: a proof-of-concept study

Adverse Experiences Resulting in Emergency Medical Treatment Seeking Following the use of Magic Mushrooms

The University of Alabama Study suggests psychedelic drugs could reduce criminal behavior

John Hopkins Study on Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey

Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006 Nov;67(11):1735-40. doi: 10.4088/jcp.v67n1110. PMID: 17196053.

Smith, M. L., Ferris, J., & Staines, G. (2018). Acute safety and tolerability of psilocybin in healthy volunteers. The American Journal of Drug and Alcohol Abuse, 44(6), 668-676.

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983-992.

Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., ... & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry, 3(7), 619-627.

Garcia-Romeu, A., Griffiths, R. R., & Johnson, M. W. (2014). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews, 7(3), 157-164.

Rosenbaum, C., Pynes, J., Oberlander, J., Levenson, J., Kuramoto, L., Halberstadt, A. L., ... & Clements, C. (2021). Safety and efficacy of psilocybin therapy for PTSD symptoms: A randomized controlled trial. Journal of Psychopharmacology.

Varker T, Watson L, Gibson K, Forbes D, O'Donnell ML. Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin. J Psychoactive Drugs. 2021 Jan-Mar;53(1):85-95. doi: 10.1080/02791072.2020.1817639. Epub 2020 Sep 15. PMID: 32931403.

Bogenschutz, M. P., & Johnson, M. W. (2015). Psilocybin-assisted psychotherapy for PTSD. The Journal of Nervous and Mental Disease, 203(4), 271-281.

Griffiths, R. R., Richards, W. A., Johnson, M. W., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268-283

Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., & MacLean, K. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology, 22(6), 621-632.